PMA device
Elecsys HBsAg II
Roche Diagnostics, Inc. · Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM, Class II) · First FDA decision Dec 23, 2016, newest Apr 24, 2023HIV, hepatitis and sexually transmitted infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
PMA pathway
Device trials
0
Naming "Elecsys HBsAg II"
MAUDE reports
318
Brand "Elecsys HBsAg II", since 2015
PubMed studies
30
Mentioning "Elecsys HBsAg II"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys HBsAg II
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 8 decisions filed under this name.
- Elecsys HBsAg II, PreciControl HBsAg II, Elecsys HBsAg Confirmatory Test, Elecsys HBsAg II Auto Confirm, PreciControl HBPMA supplement
P160019-S014 · Decided Apr 24, 2023 · 165 days after receipt · Normal 180 Day Track
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Older decisions: P160019-S001, P160019
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hepatitis Panel/Acute Hepatitis PanelNational determinationOn the books190.33Updated Oct 1, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisUnder reviewCAG-00436RUpdated Sep 23, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisReview closedCAG-00436NUpdated Sep 22, 2026
- Screening for Hepatitis B Virus (HBV) InfectionNational analysisReview closedCAG-00447NUpdated Sep 22, 2026
- Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.5, Other nonspecific abnormal serum enzyme levels, as a covered indication)Coding analysisReview closedCAG-00335NUpdated Sep 14, 2026
- Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.4, Elevation of Levels of Transaminase or Lactic Acid Dehydrogenase)Coding analysisReview closedCAG-00304NUpdated Sep 14, 2026
- Hepatitis Panel (Removal of ICD-9-CM Code 784.69, Other symbolic dysfunction, from the list of Codes Covered by Medicare)Coding analysisReview closedCAG-00283NUpdated Sep 14, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational determinationOn the books210.13Updated Apr 7, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys HBsAg II", any status and sponsor, newest update first.
No registered device study names "Elecsys HBsAg II".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys HBsAg II", and for the whole product code for context.
This brand
318 reports: 318 malfunction, 0 injury, 0 death
Whole product code LOM
2,194 reports: 2,179 malfunction, 14 injury, 0 death
Newest reports for this brand
- Elecsys HBsAg IIMalfunction
1823260-2026-04492 · Received Oct 29, 2026 · Event dated Oct 6, 2026
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM)
Device problem as coded: False Positive Result; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Elecsys HBsAg II"[tiab]. The summary above synthesizes these.
- Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.
Liu WW, Wang AZ, Xie FY, et al. · Clin Lab · 2015Clinical Trial, Comparative Study
- Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results.
Lee J, Lee SY, Cho YG, et al. · Medicina (Kaunas) · 2023
- Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Maylin S, Boyd A, Delaugerre C, et al. · Clin Vaccine Immunol · 2012Comparative Study, Research Support, Non-U.S. Gov't
- Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic hepatitis B.
Karagoz E, Selek MB, Tanoglu A, et al. · Infez Med · 2016Comparative Study
- Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients.
Liao CC, Hsu CW, Gu PW, et al. · Biomed J · 2015Comparative Study, Research Support, Non-U.S. Gov't
- A study of performance evaluation of cobas e 801 infectious diseases panel.
Jiang F, Ji Y, Liu Y, et al. · J Virol Methods · 2021Research Support, Non-U.S. Gov't
- Aerosol formation during processing of potentially infectious samples on Roche immunochemistry analyzers (cobas e analyzers) and in an end-to-end laboratory workflow to model SARS-CoV-2 infection risk for laboratory operators.
Burghardt GV, Eckl M, Huether D, et al. · Front Public Health · 2022Research Support, Non-U.S. Gov't
- Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen.
Park J, Bae T, Cho Y, et al. · Medicina (Kaunas) · 2021
- Analytical Performance Comparison of Three Quantitative Hepatitis B Surface Antigen Assays.
Ko YJ, Castor J, Kuralt TD, et al. · Clin Chem · 2026Comparative Study
- Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay.
Zacher BJ, Moriconi F, Bowden S, et al. · Clin Vaccine Immunol · 2011Evaluation Study, Multicenter Study
- Frequency of hepatitis B surface antigen variants (HBsAg) in hepatitis B virus genotype B and C infected East- and Southeast Asian patients: Detection by the Elecsys® HBsAg II assay.
Kim HS, Chen X, Xu M, et al. · J Clin Virol · 2018Research Support, Non-U.S. Gov't
- Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay.
Gencay M, Vermeulen M, Neofytos D, et al. · J Clin Virol · 2018Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LOM.
- VITROS Immunodiagnostic Products Anti-HBc Reagent Pack and CalibratorOrtho-Clinical Diagnostics · PMA 2018
- Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgMRoche Diagnostics Corp. · PMA 2024
- Advia Centaur Hbc IGM Readypack ReagentsSiemens Healthcare Diagnostics · PMA 2016
- Immulite/Immulite 1000 & Immulite 2000 Anti-HbsSiemens Healthcare Diagnostics Products, Ltd. · PMA 2010
- Architect AusabAbbott Laboratories, Inc. · PMA 2024
- Elecsys Anti-HBc IIRoche Diagnostics Corp. · PMA 2023
- Architect Core-MAbbott Laboratories · PMA 2020
- ADVIA Centaur HBsAgII (HBsII)Siemens Corp. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.